SCHEMBL277162

SCHEMBL277162

CC(C)C(C)N(C=O)C(C)C(C)C

nearest known ligand 0.34

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL271409 0.78
SCHEMBL25307 0.72
SCHEMBL276461 0.71 ALOX15 (0.34) TSHRALOX15
SCHEMBL31267367 0.69 TSHR (0.36) TSHRALOX15
Hydrochloric Acid SCHEMBL16586150 0.69 TSHR (0.36) TSHRALOX15
SCHEMBL31602200 0.69 TSHR (0.36) TSHRALOX15
SCHEMBL277535 0.69 TSHR (0.32) TSHRALOX15
SCHEMBL6841022 0.67
SCHEMBL276168 0.65 ALOX15 (0.34) TSHRALOX15
SCHEMBL269689 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-10-19 US disclosed
US-11731971-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-08-22 US disclosed
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-12-02 US disclosed
US-11117896-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-09-14 US disclosed
US-20200048253-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2020-02-13 US disclosed
US-10556905-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2020-02-11 US disclosed
EP-2857401-B1 NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME MEIJI SEIKA PHARMA CO LTD (JP) 2019-09-18 EP disclosed
US-20180258089-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-09-13 US disclosed
US-10023573-B2 Beta-lactamase inhibitor and process for preparing the same MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-07-17 US disclosed
US-20170233393-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME MEIJI SEIKA PHARMA CO., LTD. (JP) 2017-08-17 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-2025671-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2009-02-18 EP disclosed
EP-1953147-A1 HETEROCYCLIC COMPOUND AND MEDICINAL APPLICATION THEREOF Japan Tobacco, Inc. (JP) 2008-08-06 EP disclosed
EP-1947101-A1 HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2008-07-23 EP disclosed
US-20070255064-A1 Imidazolium-Methyl Sulfites for Use as Starting Compounds for Producing Ionic Liquids BASF AKTIENGESELLSCHAFT (DE) 2007-11-01 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed
EP-1819692-A1 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS Nissan Chemical Industries, Ltd. (JP) 2007-08-22 EP disclosed
EP-1786780-A1 IMIDAZOLIUM-METHYL SULFITES FOR USE AS STARTING COMPOUNDS FOR PRODUCING IONIC LIQUIDS BASF AKTIENGESELLSCHAFT (DE) 2007-05-23 EP disclosed
WO-2006062240-A1 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2006-06-15 WO disclosed
WO-2006021303-A1 IMIDAZOLIUM-METHYL SULFITES FOR USE AS STARTING COMPOUNDS FOR PRODUCING IONIC LIQUIDS BASF AKTIENGESELLSCHAFT (DE) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731971-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 TSHR 1888/4885ALOX15 1150/4885
US-20200048253-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 TSHR 1888/4885ALOX15 1150/4885
US-20070255064-A1 Imidazolium-Methyl Sulfites for Use as Starting Compounds for Producing Ionic Liquids CBR3, SCO2, PRMT5 TSHR 2749/4885ALOX15 77/4885
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL TSHR 46/4885ALOX15 1391/4885
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 TSHR 1888/4885ALOX15 1150/4885
US-20180258089-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 TSHR 1888/4885ALOX15 1150/4885
US-10023573-B2 Beta-lactamase inhibitor and process for preparing the same FN1, FNTB, CPN1 TSHR 3303/4885ALOX15 1010/4885
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 TSHR 1888/4885ALOX15 1150/4885
US-10556905-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 TSHR 1888/4885ALOX15 1150/4885
US-20170233393-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME FN1, FNTB, CPN1 TSHR 3303/4885ALOX15 1010/4885
US-11117896-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 TSHR 1888/4885ALOX15 1150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.